Identification and characterization of protective CD8(+) T‐epitopes in a malaria vaccine candidate SLTRiP

INTRODUCTION: Efforts are required at developing an effective vaccine that can inhibit malaria prevalence and transmission. Identifying the critical immunogenic antigens and understanding their interactions with host proteins forms a major focus of subunit vaccine development. Previously, our laboratory showed that SLTRiP conferred protection to the liver stage of Plasmodium growth in rodents. In the follow‐up of earlier research, we demonstrate that SLTRiP‐mediated protection is majorly concentrated in specific regions of protein. METHOD: To identify particular protective regions of protein, we synthesized multiple nonoverlapping fragments from SLTRiP protein. From this, we designed a panel of 8‐20mer synthetic peptides, which were predicted using T‐epitope‐based prediction algorithm. We utilized the IFN‐γ enzyme‐linked immunosorbent spot assay to identify immunodominant peptides. The latter were used to immunize mice, and these mice were challenged to assess protection. RESULTS: The protective polypeptide fragment SLTRiP C3 and SLTRiP C4 were identified, by expressing and testing multiple fragments of PbSLTRiP protein. The immune responses generated by these fragments were compared to identify the immunodominant fragment. The T‐epitopes were predicted from SLTRiP protein using computer‐based algorithms. The in vitro immune responses generated by these peptides were compared with each other to identify the immunodominant T‐epitope. Immunization using these peptides showed significant reduction in parasite numbers during liver stage. CONCLUSION: Our findings show that the protective efficacy shown by SLTRiP is localized in particular protein fragments. The peptides designed from such regions showed protective efficacy equivalent to whole protein. The sequence conservation analysis with human Plasmodium species also showed that these peptides were conserved. In conclusion, these peptides or their equivalent from other Plasmodium species could impart protection against malaria in their respective hosts too. Our studies provide a basis for the inclusion of these peptides in clinical vaccine constructs against malaria.